181) ualities of higher potency Foot-and-Mouth Disease (FMD) vaccines, performance of dif |
182) An outbreak of foot-and-mouth disease (FMD) causes huge economic losses |
183) armers due to outbreaks of foot and mouth disease (FMD) in 2010-12 in northern Laos |
184) The largest epidemic of foot-and-mouth disease (FMD) in Korea since the first rec |
185) o-temporal distribution of foot-and-mouth disease (FMD) in Tanzania. |
186) Control of foot-and-mouth disease (FMD) in Uganda by ring vaccinatio |
187) Foot-and-mouth disease (FMD) is endemic in Bangladesh and |
188) Foot-and-mouth disease (FMD) is endemic in Kenya where fo |
189) Foot-and-mouth disease (FMD) vaccines are routinely used |
190) est explains variations in cardiovascular disease risk across populations. |
191) After the non-communicable disease risk factor levels of participants |
192) uced similar reductions in cardiovascular disease risk factors compared with hospita |
193) Correlations for other noncommunicable disease risk factors were analyzed before |
194) central obesity and other noncommunicable disease risk factors were assessed. |
195) central obesity and other noncommunicable disease risk factors. |
196) body mass index (BMI) with cardiovascular disease risk in a Chinese population. |
197) of-care testing device for cardiovascular disease risk. |
198) Disease severity was assessed using the Ps |
199) verity of genital involvement and overall disease severity and body mass index. |
200) stigate changes in quality of life (QoL), disease severity and exercise tolerance of |
201) ransition probabilities between states of disease severity are inferred indirectly f |
202) Even in the presence of disease severity in patients with New York |
203) Health related QoL, disease severity measured by B-type natriu |
204) f severe impact of psoriasis on HRQoL was disease severity. |
205) s current statistical inference regarding disease progression and cognitive function |
206) histologically disparate but show similar disease progression and response to therap |
207) hese dogs, but none of the others, showed disease progression. |
208) sm by which these proteases contribute to disease progression. |
209) concerned the involvement of bacteria in disease progression. |
210) oglia subtypes with peculiar functions in disease progression. |
211) erging zoonotic mosquito-borne infectious disease that has been identified as a risk |
212) Asthma is a highly prevalent disease that may affect the lifestyle adop |
213) Rhabdomyosarcoma is a disease that predominantly affects childre |
|